Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 19

1.
2.

EPS profiles: the atypical antipsychotics are not all the same.

Weiden PJ.

J Psychiatr Pract. 2007 Jan;13(1):13-24. Review.

PMID:
17242588
3.

[Extrapyramidal side-effects: avoidance, diagnosis and treatment].

Fleischhacker WW, Widschwendter C.

Psychiatr Prax. 2005 Apr;32 Suppl 1:S25-30. Review. German.

PMID:
15818517
4.

Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome.

Shirzadi AA, Ghaemi SN.

Harv Rev Psychiatry. 2006 May-Jun;14(3):152-64. Review.

PMID:
16787887
5.

The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia.

Haro JM, Salvador-Carulla L.

CNS Drugs. 2006;20(4):293-301. Review.

PMID:
16599647
6.

Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medications.

Weiden PJ, Buckley PF.

J Clin Psychiatry. 2007;68 Suppl 6:14-23. Review.

PMID:
17650055
7.

Akathisia: problem of history or concern of today.

Iqbal N, Lambert T, Masand P.

CNS Spectr. 2007 Sep;12(9 Suppl 14):1-13. Review.

PMID:
17805218
9.

Switching antipsychotics: an updated review with a focus on quetiapine.

Weiden PJ.

J Psychopharmacol. 2006 Jan;20(1):104-18. Epub 2005 Oct 4. Review.

PMID:
16204323
10.

Prolactin awareness: an essential consideration for physical health in schizophrenia.

Montejo AL.

Eur Neuropsychopharmacol. 2008 May;18 Suppl 2:S108-14. doi: 10.1016/j.euroneuro.2008.02.004. Review.

PMID:
18346598
11.

Neurological complications of psychiatric drugs: clinical features and management.

Haddad PM, Dursun SM.

Hum Psychopharmacol. 2008 Jan;23 Suppl 1:15-26. Review.

PMID:
18098217
12.

[Use of antidepressant drugs in schizophrenic patients with depression].

Micallef J, Fakra E, Blin O.

Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. Review. French.

PMID:
16910628
13.

Dosing atypical antipsychotics.

Cutler A, Ball S, Stahl SM.

CNS Spectr. 2008 May;13(5 Suppl 9):1-16. Review.

PMID:
18496483
14.

Evolution of antipsychotic intervention in the schizophrenic psychosis.

Garver DL.

Curr Drug Targets. 2006 Sep;7(9):1205-15. Review.

PMID:
17017896
15.

Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles.

Nasrallah HA.

Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. Review.

PMID:
17848919
16.

Sertindole: efficacy and safety in schizophrenia.

Lindström E, Levander S.

Expert Opin Pharmacother. 2006 Sep;7(13):1825-34. Review.

PMID:
16925508
17.

Priapism associated with atypical antipsychotic medications: a review.

Sood S, James W, Bailon MJ.

Int Clin Psychopharmacol. 2008 Jan;23(1):9-17. Review.

PMID:
18090503
18.

Antipsychotic safety and efficacy concerns.

Meyer JM.

J Clin Psychiatry. 2007;68 Suppl 14:20-6. Review.

PMID:
18284274
19.

The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.

Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP; Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness.

J Clin Psychiatry. 2009;70 Suppl 4:1-46; quiz 47-8. Review.

PMID:
19686636
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk